SEC Form 4 · accession 0001209191-15-025201

CONCERT PHARMACEUTICALS, INC. · CNCE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — VP, Finance

Period of report

Mar 10, 2015

Accepted (ET)

Mar 11, 2015 · 4:40 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001367920

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 10, 2015	M	8,849	$1.13	A	8,849	D
Common Stock^F3	Mar 10, 2015	S	8,849	$13.90	D	0	D
Common Stock	Mar 10, 2015	M	6,194	$1.13	A	6,194	D
Common Stock^F3	Mar 10, 2015	S	6,194	$13.90	D	0	D
Common Stock	Mar 10, 2015	M	7,079	$3.79	A	7,079	D
Common Stock^F3	Mar 10, 2015	S	7,079	$13.90	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Employee Stock Option (right to buy)^F4	$1.13	Mar 10, 2015	M	8,849	D	—	Jun 4, 2017	Common Stock	8,849	D
Employee Stock Option (right to buy)^F4	$1.13	Mar 10, 2015	M	6,194	D	—	Dec 11, 2017	Common Stock	6,194	D
Employee Stock Option (right to buy)^F4	$3.79	Mar 10, 2015	M	7,079	D	—	Dec 3, 2020	Common Stock	7,079	D

F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $13.68 to $14.29. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4Immediately.